



Investor Contact:
Rick Buchholz
rickbuchholz@inspiresleep.com
(612) 889-8747

Media Contact:
Howard Green
howardgreen@inspiresleep.com
(651) 357-3616

Inspire Medical Systems Ranks #2 on Cleveland Clinic's List of the Top 10 Medical Innovations for 2018

Neuromodulation to treat Obstructive Sleep Apnea selected from among 300 nominated medical innovations

MINNEAPOLIS (November 1, 2017) — Inspire Medical Systems, Inc., the manufacturer of the only FDA-approved active implantable device for obstructive sleep apnea (OSA), announced today that its Inspire therapy was selected the #2 ranked medical innovation that “has the power to transform healthcare in 2018” by a panel of top physicians and researchers at the Cleveland Clinic.

“We have seen significant improvements in patient outcomes with Inspire therapy at the Cleveland Clinic since FDA approval in 2014,” said Alan H. Kominsky, M.D., Director of the Cleveland Clinic Otolaryngology Residency Program. “We look forward to continuing to deliver this transformative medical innovation to our patients at the Cleveland Clinic in 2018 and beyond.”

Inspire therapy is an FDA-approved treatment for moderate-to-severe sleep apnea patients who are unable to use CPAP, and has been implanted in over 2,000 patients worldwide since 2014. This small device is implanted under the skin during an outpatient surgical procedure. Once implanted, the Inspire neurostimulator delivers mild stimulation to the hypoglossal nerve, which controls the muscles and movements of the tongue, thereby stabilizing the upper airway and improving airflow during sleep. Patients use a sleep remote to turn the therapy on when they go to bed, and can adjust their own therapy, as necessary.

“Each year, the Cleveland Clinic names their top 10 medical innovations for the coming year, and we are thrilled to be #2 on this list for 2018,” said Tim Herbert, CEO of Inspire Medical Systems. “We are proud of the patient outcomes generated to date with our Inspire therapy. Our collaborative relationship with physicians and allied health professionals in the United States and Europe, including the Cleveland Clinic, is critical to bringing Inspire therapy to those obstructive sleep apnea patients who do not derive a benefit from CPAP.”

A link to the press release from the Cleveland Clinic announcing the full top-10 list can be found at: <http://cle.clinic/2z9bGdR>.

In a related publication entitled, “*Impact of Hypoglossal Nerve Stimulation on Early Patient Reported Outcomes: The Cleveland Clinic Experience*”, published in the April

27, 2017 issue of SLEEP, an international journal focused on sleep and circadian science, Dr. Kominsky and his associates from the Cleveland Clinic presented the results of their independent study evaluating patients who were prescribed Inspire therapy. The investigators' initial hypothesis noted that while published data support the long-term benefit and durability of hypoglossal nerve stimulation on patient reported outcomes, the effect on depression and insomnia indices remained unclear.

The results of this study confirmed prior findings of Inspire therapy, as the treatment generated improvement in self-reported dozing propensity and sleepiness impact on a patient's quality of life. Additional, new findings, showed an early and clinically significant improvement in depression scores and a trend for improvement in insomnia. The investigators noted that larger-scale and longer-term studies are needed to more fully examine the extent and sustainability on depression and insomnia symptoms.

About Inspire Therapy

Inspire Upper Airway Stimulation therapy, or also known as Cranial Nerve (XII) Stimulation therapy, is an FDA-approved treatment for some people with moderate to severe Obstructive Sleep Apnea who are unable to use or get consistent benefit from continuous positive airway pressure (CPAP). In contrast to CPAP, Inspire therapy is implanted inside the body and works with a patient's natural breathing process. Controlled by the small handheld sleep remote, the system includes a breathing sensor and a stimulation lead powered by a neurostimulator. During sleep, the Inspire system senses breathing patterns and delivers mild stimulation to the tongue and other soft tissues of the throat to keep the airway open. Inspire therapy is currently available at over 150 leading medical centers across the United States and Europe.

About Inspire Medical Systems, Inc.

Inspire Medical Systems, Inc., based in Minneapolis, Minn., was founded with the purpose of developing a safe, effective and well-accepted therapy to help those OSA patients who are unable to tolerate or get relief from CPAP. Inspire therapy is the world's first implantable FDA-approved neurostimulation system for the treatment of OSA. The Company is privately held and investors include Amzak Health, Aperture Venture Partners, GDN Holdings, Johnson & Johnson, Kleiner Perkins Caufield & Byers, Medtronic, OrbiMed Advisors, Synergy Life Science Partners, TGap Ventures and US Venture Partners.

For more information, visit www.InspireSleep.com.